TS Pharma will market the product in Antigua, Aruba, Bahamas, Barbados, Belize, Bermuda, Cayman Islands, Costa Rica, Curacao, Netherland Antilles, Dominican Republic, El Salvador, Guatemala, Haiti, Honduras, Jamaica, Panama, and Trinidad & Tobago.

Onko-Sure is a simple, non-invasive blood test used for the detection and/or monitoring of 15 different types of cancers.

Radient chairman and CEO Douglas MacLellan said with this agreement, they are making Onko-Sure available in additional new markets.